Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia
- PMID: 37137801
- DOI: 10.1016/j.jacl.2023.04.003
Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia
Conflict of interest statement
Conflicts of interest None.
Comment in
-
Evidence regarding SGLT-2 inhibitors for the management of diabetic dyslipidemia.J Clin Lipidol. 2023 May-Jun;17(3):422-423. doi: 10.1016/j.jacl.2023.04.006. Epub 2023 Apr 28. J Clin Lipidol. 2023. PMID: 37164839 No abstract available.
Comment on
-
Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India.J Clin Lipidol. 2023 Mar-Apr;17(2):e1-e14. doi: 10.1016/j.jacl.2022.11.002. Epub 2022 Nov 23. J Clin Lipidol. 2023. PMID: 36577628
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical